Discussion
The physiological role of Interleukin 6 (IL-6) has been advised to participation in the pathogenesis of several diseases. These introduce multiple myeloma, post-menopausal osteoporosis, and chronic autoimmune diseases, where a stable association has been shown between disease changes and increased production of the cytokine. For these reasons it is commonly believed that potent IL-6 receptor antagonists will be helpful therapeutic tools [4].
On the other hand, the renin-angiotensin system (RAS), a peptide based system, has been classically recognized as a complex linear humoral system. It gives to the control of cardiovascular, renal, and adrenal functions [1]. The circulatory protease, renin is a key enzyme of the RAS and is secreted. The RAS is one of the central members in respiratory diseases such as acute respiratory distress syndrome (ARDS) and acute lung injury (ALI) during sepsis [5]. ARDS is characterized by pulmonary edema, severe hypoxia, and accumulation of inflammatory cells [10]. One of the common indications of ARDS is a strong inflammatory response, which is characterized by the release of proinflammatory cytokines [5].
The effect of RAS is well known in the cardiovascular system in specific in the control of blood pressure, vasoconstriction, cell growth and cardiac remodelling. Inflammation and oxidative stress play an important role with it [6].
Also, Rheumatoid arthritis (RA) is an inflammatory disease of joints. It is related with increased risk of cardiovascular complications. The main disadvantageous contributing factor for an increased mortality in RA is the extent of associated systemic inflammation. Then it is opinion that drugs was guessed can be effective and is suggested that pepstatin inhibitor can be appropriate on interaction with SARS-CoV-2 for future work.
Two models of chemical series selected from the above mentioned database were modified these compounds by including substituents to have interactions with SARS-CoV-2 spike protein receptor residues at S1 subunit.
The purpose of this article was to brief about antiSARS-CoV-2 spike protein drugs (Pharmacokinetics and pharmacodynamics). Activated inflammation, as demonstrated by persistently higher IL-6 levels, may have profound and far-reaching clinical implications [16]. Even when virologically contained, treated HIV-infected persons have significantly higher plasma levels of IL-6 than well-matched uninfected controls [17]. Changes in cytokine levels in HIV infected individuals can affect the function of the immune system and have the potential to directly impact the course of HIV disease effects of cytokines are pleiotropic and are influenced by the concentrations, presence or absence of other cytokines. Once produced, these factors may act individually or together, directly or indirectly on infected cells, activating cellular components of the intrinsic system and/or promoting specific T- and B-cell adaptive responses to mediate anti-microbial effects [18].
There are a number of pharmaceuticals before being tested, but a better understanding of the underlying pathobiology is required. In this context, this article was briefly reviewed the hypothesis for SARS-CoV-2 spike protein receptor as a specific target.
The same protocol applied to drugs forming complexes with ASN479. Analysis of the number of hydrogen and hydrophobic bonds between drugs and protein shows that the complex has a higher number of intermolecular Van der Waals bonds, which indicates that it has higher affinity for TYR442, TRP476, LEU478, LYS439 and ASP480 than others.
Theoretically, lostartan was the lowest energy obtained in docking simulations, so that should be the best selection, but comparison RefRMSs to expression standard deviation and the consideration inhibitor constant, lamirudine can be the most effective and then favipiravir as well as in the end, chloroquine, respectively. Hawever, anakinra is proposed, because the only structure that interact with SARS-CoV-2 spike protein by simulation vina software (Figure1-a).